Latest News and Press Releases

WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will host an Investor Day on Friday, June 8, 2018 in New York City starting at 8:00 a.m....

WALTHAM, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive officer and Pepe Carmona, Senior Vice President...

First quarter 2018 TYMLOS® sales increase to $14.5 million, a 90% increase over the fourth quarter of 2017 TYMLOS captured on average 13% of the U.S. anabolic osteoporosis market and 31% of new...

WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter financial results on Thursday, May 10, 2018. The Company will...

WALTHAM, Mass., March 30, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the company has initiated the Phase 3 ATOM (Abaloparatide Treatment for Osteoporosis in...

WALTHAM, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...

WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...

WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...

WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at Cowen’s...

TYMLOS™ sales show accelerating market share growth, capturing approximately 32% of osteoporosis patients new to anabolic therapy Abaloparatide patch program advances with FDA alignment on regulatory...